168 related articles for article (PubMed ID: 11745440)
1. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.
Berd D; Sato T; Cohn H; Maguire HC; Mastrangelo MJ
Int J Cancer; 2001 Nov; 94(4):531-9. PubMed ID: 11745440
[TBL] [Abstract][Full Text] [Related]
2. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.
Berd D; Sato T; Mastrangelo MJ
Cancer Immunol Immunother; 2002 Aug; 51(6):320-6. PubMed ID: 12111120
[TBL] [Abstract][Full Text] [Related]
3. M-Vax: an autologous, hapten-modified vaccine for human cancer.
Berd D
Expert Rev Vaccines; 2004 Oct; 3(5):521-7. PubMed ID: 15485331
[TBL] [Abstract][Full Text] [Related]
4. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
Berd D; Sato T; Maguire HC; Kairys J; Mastrangelo MJ
J Clin Oncol; 2004 Feb; 22(3):403-15. PubMed ID: 14691123
[TBL] [Abstract][Full Text] [Related]
5. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.
Berd D; Maguire HC; Schuchter LM; Hamilton R; Hauck WW; Sato T; Mastrangelo MJ
J Clin Oncol; 1997 Jun; 15(6):2359-70. PubMed ID: 9196151
[TBL] [Abstract][Full Text] [Related]
6. M-Vax: an autologous, hapten-modified vaccine for human cancer.
Berd D
Expert Opin Biol Ther; 2002 Mar; 2(3):335-42. PubMed ID: 11890872
[TBL] [Abstract][Full Text] [Related]
7. Autologous, hapten-modified vaccine as a treatment for human cancers.
Berd D; Kairys J; Dunton C; Mastrangelo MJ; Sato T; Maguire HC
Semin Oncol; 1998 Dec; 25(6):646-53. PubMed ID: 9865679
[TBL] [Abstract][Full Text] [Related]
8. Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccine.
Berd D
Vaccine; 2003 Jan; 21(7-8):795-7. PubMed ID: 12531362
[TBL] [Abstract][Full Text] [Related]
9. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
Berd D; Mastrangelo MJ
Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
[TBL] [Abstract][Full Text] [Related]
10. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
Berd D; Maguire HC; McCue P; Mastrangelo MJ
J Clin Oncol; 1990 Nov; 8(11):1858-67. PubMed ID: 2230873
[TBL] [Abstract][Full Text] [Related]
11. Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides.
Sato T; Bullock TN; Eisenlohr LC; Mastrangelo MJ; Berd D
Clin Immunol Immunopathol; 1997 Dec; 85(3):265-72. PubMed ID: 9400626
[TBL] [Abstract][Full Text] [Related]
12. Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine.
Sato T
Cancer Immunol Immunother; 1996 Nov; 43(3):174-9. PubMed ID: 9001571
[TBL] [Abstract][Full Text] [Related]
13. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.
Berd D; Maguire HC; Mastrangelo MJ
Cancer Res; 1986 May; 46(5):2572-7. PubMed ID: 3697996
[TBL] [Abstract][Full Text] [Related]
14. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine.
Mahipal A; Terai M; Berd D; Chervoneva I; Patel K; Mastrangelo MJ; Sato T
Cancer Immunol Immunother; 2011 Jul; 60(7):1039-45. PubMed ID: 21519827
[TBL] [Abstract][Full Text] [Related]
15. Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy.
Murphy GF; Radu A; Kaminer M; Berd D
J Invest Dermatol; 1993 Mar; 100(3):335S-341S. PubMed ID: 8440919
[TBL] [Abstract][Full Text] [Related]
16. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
Hsueh EC; Essner R; Foshag LJ; Ollila DW; Gammon G; O'Day SJ; Boasberg PD; Stern SL; Ye X; Morton DL
J Clin Oncol; 2002 Dec; 20(23):4549-54. PubMed ID: 12454111
[TBL] [Abstract][Full Text] [Related]
17. Autologous, hapten-modified vaccine as a treatment for human cancers.
Berd D
Vaccine; 2001 Mar; 19(17-19):2565-70. PubMed ID: 11257393
[TBL] [Abstract][Full Text] [Related]
18. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.
O'Rourke MG; Johnson M; Lanagan C; See J; Yang J; Bell JR; Slater GJ; Kerr BM; Crowe B; Purdie DM; Elliott SL; Ellem KA; Schmidt CW
Cancer Immunol Immunother; 2003 Jun; 52(6):387-95. PubMed ID: 12682787
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study.
Schreiber S; Kämpgen E; Wagner E; Pirkhammer D; Trcka J; Korschan H; Lindemann A; Dorffner R; Kittler H; Kasteliz F; Küpcü Z; Sinski A; Zatloukal K; Buschle M; Schmidt W; Birnstiel M; Kempe RE; Voigt T; Weber HA; Pehamberger H; Mertelsmann R; Bröcker EB; Wolff K; Stingl G
Hum Gene Ther; 1999 Apr; 10(6):983-93. PubMed ID: 10223732
[TBL] [Abstract][Full Text] [Related]
20. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
